TY - JOUR
T1 - Klinička praksa temeljena na dokazima
T2 - Pregled prijetnji valjanosti dokaza i kako ih spriječiti
AU - Garattini, Silvio
AU - Jakobsen, Janus C.
AU - Wetterslev, Jørn
AU - Bertele, Vittorio
AU - Banzi, Rita
AU - Rath, Ana
AU - Neugebauer, Edmund A.M.
AU - Laville, Martine
AU - Masson, Yvonne
AU - Hivert, Virginie
AU - Eikermann, Michaela
AU - Aydin, Burc
AU - Ngwabyt, Sandra
AU - Martinho, Cecilia
AU - Gerardi, Chiara
AU - Szmigielski, Cezary A.
AU - Demotes-Maynard, Jacques
AU - Gluud, Christian
PY - 2017/12
Y1 - 2017/12
N2 - Using the best quality of clinical research evidence is essential for choosing the right treatment for patients. How to identify the best research evidence is, however, difficult. In this narrative review we summarise these threats and describe how to minimise them. Pertinent literature was considered through literature searches combined with personal files. Treatments should generally not be chosen based only on evidence from observational studies or single randomised clinical trials. Systematic reviews with meta-analysis of all identifiable randomised clinical trials with Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment represent the highest level of evidence. Even though systematic reviews are trust worthier than other types of evidence, all levels of the evidence hierarchy are under threats from systematic errors (bias); design errors (abuse of surrogate outcomes, composite outcomes, etc.); and random errors (play of chance). Clinical research infrastructures may help in providing larger and better conducted trials. Trial Sequential Analysis may help in deciding when there is sufficient evidence in meta-analyses. If threats to the validity of clinical research are carefully considered and minimised, research results will be more valid and this will benefit patients and heath care systems.
AB - Using the best quality of clinical research evidence is essential for choosing the right treatment for patients. How to identify the best research evidence is, however, difficult. In this narrative review we summarise these threats and describe how to minimise them. Pertinent literature was considered through literature searches combined with personal files. Treatments should generally not be chosen based only on evidence from observational studies or single randomised clinical trials. Systematic reviews with meta-analysis of all identifiable randomised clinical trials with Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment represent the highest level of evidence. Even though systematic reviews are trust worthier than other types of evidence, all levels of the evidence hierarchy are under threats from systematic errors (bias); design errors (abuse of surrogate outcomes, composite outcomes, etc.); and random errors (play of chance). Clinical research infrastructures may help in providing larger and better conducted trials. Trial Sequential Analysis may help in deciding when there is sufficient evidence in meta-analyses. If threats to the validity of clinical research are carefully considered and minimised, research results will be more valid and this will benefit patients and heath care systems.
KW - Evidence-based clinical practice
KW - Evidence-based medicine
KW - Meta-analysis
KW - Randomised clinical trial
KW - Systematic review
KW - Trial sequential analysis
UR - https://www.scopus.com/pages/publications/85037067704
U2 - 10.21860/medflum2017_187362
DO - 10.21860/medflum2017_187362
M3 - Review
AN - SCOPUS:85037067704
SN - 1847-6864
VL - 53
SP - 424
EP - 438
JO - Medicina Fluminensis
JF - Medicina Fluminensis
IS - 4
ER -